FIELD: medicine.
SUBSTANCE: invention refers to medicine, particularly to neurology and concerns the EGF/GHRP-6 combination for central nervous system neuroregeneration after an autoimmune damage. Substance of the invention involves a pharmaceutical combination which represents therapeutically effective concentrations of epidermal growth factor (EGF) and growth hormone releasing peptide-6 (GHRP - 6) and which is introduced in an individual who suffers the symptoms of multiple sclerosis and neuromyelitis optica, and corrects demyelinisation in the central nervous system caused by autoreactive cells.
EFFECT: improved clinical effectiveness.
8 cl, 4 ex, 8 tbl
Title | Year | Author | Number |
---|---|---|---|
APPLICATION OF 5'-METHYLTHIOADENOSINE (MTA) FOR PREVENTION AND/OR TREATMENT OF AUTOIMMUNE DISEASES AND/OR GRAFT REJECTION | 2005 |
|
RU2393866C2 |
NEW TREATMENT OF MULTIPLE SCLEROSIS (MS) | 2011 |
|
RU2595861C2 |
GHRP-6-CONTAINING PHARMACEUTICAL COMPOSITION FOR PREVENTION AND REMOVAL OF FIBROSIS AND OTHER PATHOLOGICAL DEPOSITS IN TISSUES | 2007 |
|
RU2465913C2 |
COMPOSITIONS FOR TREATMENT OF DISSEMINATED SCLEROSIS | 2008 |
|
RU2492234C2 |
COMPOUNDS AND PHARMACEUTIC COMBINATIONS FOR TREATMENT OF NEURODEGENERATIVE AND ISCHEMIC BRAIN DISEASES | 2012 |
|
RU2569302C2 |
PHARMACEUTICAL COMBINATION INCLUDING EPIDERMAL GROWTH FACTOR AND GHRP6 PEPTIDE AS A SECRETION STIMULATOR FOR RECOVERY AFTER BRAIN DAMAGE | 2019 |
|
RU2776812C1 |
AGONISTS OF NEUROTROPHIN RECEPTORS AND THEIR USE AS MEDICAMENTS | 2011 |
|
RU2606622C2 |
TREATMENT OF AUTOIMMUNE DISEASES | 2006 |
|
RU2424795C2 |
LACTOBACILLUS APPLICATION FOR TREATING AUTOIMMUNE DISEASES | 2006 |
|
RU2417092C2 |
TREATING AUTOIMMUNE DISEASES | 2006 |
|
RU2493840C2 |
Authors
Dates
2010-11-20—Published
2006-02-24—Filed